Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Gemcitabine and Carboplatin or Oxaliplatin in Metastatic Urothelial Cancer
NCT03451331Phase 2Completed
- Start
- May 2018
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in urothelial carcinoma (UC) (2 arms). Primary endpoint: Objective Response Rate at 50 months. Started May 2018; status: completed.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03451331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03451331.